reported a higher rate of STAT3 mutations in PTCL, NOS in comparison with ALK- ALCL (17% vs. 13%), and a lower rate of JAK1/3 mutations (0 vs. 15%) (14). The gene discussed is JAK1; the disease is anaplastic large cell lymphoma.